Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

References

• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10.e2–7.
   Web of Science ®Google Scholar
• Ezzedine K, Shourick J, Merhand S, et al. Impact of atopic dermatitis in adolescents and their parents: a French study. Acta Derm Venereol. 2020;100(17):adv00294.
   PubMedGoogle Scholar
• Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007;215(2):123–129.
   PubMed Web of Science ®Google Scholar
• Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75–e91.
   PubMed Web of Science ®Google Scholar
• Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol. 1999;103(1 pt 1):125–138.
   PubMed Web of Science ®Google Scholar
• Kim JP, Chao LX, Simpson EL, et al. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681–687.e11.
   PubMed Web of Science ®Google Scholar
• Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293.
   PubMed Web of Science ®Google Scholar
• Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526.e7–1532.e7.
   Web of Science ®Google Scholar
• Fölster-Holst R. Management of atopic dermatitis: are there differences between children and adults? J Eur Acad Dermatol Venereol. 2014;28(Suppl 3):5–8.
   PubMedGoogle Scholar
• Shi B, Bangayan NJ, Curd E, et al. The skin microbiome is different in pediatric versus adult atopic dermatitis. J Allergy Clin Immunol. 2016;138(4):1233–1236.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis-a review on behalf of the international eczema council. J Allergy Clin Immunol. 2021;147(4):1174.e1–1190.e1.
   Web of Science ®Google Scholar
• Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104–112.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664.
   PubMed Web of Science ®Google Scholar
• Waters A, Sandhu D, Beattie P, et al. Severity stratification of children’s dermatology life quality index (CDLQI) scores. Br J Dermatol. 2010;163(Suppl 1):121.
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38(1):29–41.
   Web of Science ®Google Scholar
• Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergol Select. 2021;5:293–304.
   PubMedGoogle Scholar
• Basra MKA, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27–33.
   PubMed Web of Science ®Google Scholar
• Simpson EL, de Bruin-Weller M, Eckert L, et al. Responder threshold for patient-oriented eczema measure (POEM) and children’s dermatology life quality index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019;9(4):799–805.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Gori N, Narcisi A, et al. Effectiveness and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: a multicentric, prospective, real-world, cohort study. Drugs R D. 2022;22(3):245–252.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021;35(7):1543–1552.
   PubMed Web of Science ®Google Scholar
• Paller AS, Bansal A, Simpson EL, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119–131.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Boguniewicz M, et al. Dupilumab provides rapid and sustained clinically meaningful responses in adults with moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2021;101(11):adv00585.
   PubMedGoogle Scholar
• Cork MJ, McMichael A, Teng J, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcome. J Eur Acad Dermatol Venereol. 2022;36(3):422–433.
   PubMed Web of Science ®Google Scholar
• Ricci G, Bellini F, Dondi A, et al. Atopic dermatitis in adolescence. Dermatol Reports. 2012;4(1):e1.
   PubMedGoogle Scholar
• Teixeira C, Garcia MJ, Freitas A, et al. Impact of atopic dermatitis on the mental health of adolescents: literature review. Med Sci Forum. 2022;16(8):1–5.
   Google Scholar
• Grant L, Larsen LS, Trennery C, et al. Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents. Dermatitis. 2019;30(4):247–254.
   PubMed Web of Science ®Google Scholar